Search results
Showing 121 to 129 of 129 results for social wellbeing for children young people
The social care guidance manual
Show all sections
- 1 Introduction
- 2 The scope
- 3 The Guidance Development Group
- 4 Developing review questions and planning the systematic review
- 5 Identifying the evidence: literature searching and evidence submission
- 6 Reviewing the evidence
- 7 Incorporating economic evaluation
- 8 Linking social care guidance to other NICE guidance
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation.
This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
View recommendations for NG86Show all sections
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Interim methods guide for developing good practice guidance (PMG15)
Interim methods guide for developing good practice guidance